<DOC>
	<DOCNO>NCT02083627</DOCNO>
	<brief_summary>This study assess effect multiple dose fidaxomicin single dose pharmacokinetics rosuvastatin healthy male subject . Determine safety tolerability multiple dos fidaxomicin presence single dose rosuvastatin healthy male subject . Also determine pharmacokinetics multiple dos fidaxomicin metabolite OP-1118 .</brief_summary>
	<brief_title>A Study Assess Effects Multiple Doses Fidaxomicin Single Dose Rosuvastatin Healthy Male Subjects</brief_title>
	<detailed_description>Sequence 1 : Thirteen subject receive oral dose rosuvastatin Day 1 Period 1 Day 13 Period 2 twice-daily oral dos fidaxomicin Days 8 17 Period 2 , accord follow treatment schedule : - Period 1 : Subjects receive single oral dose rosuvastatin Day 1 , follow 5-day pharmacokinetic ( PK ) sample period . - Period 2 : The subject receive fidaxomicin twice daily 5 day ( Days 8 12 ) . On Day 13 , single oral dose rosuvastatin oral dose fidaxomicin administer simultaneously morning . Twice-daily treatment fidaxomicin continue end Day 17 . Subjects discharge Day 18 assessment perform medical reason prolong stay . Sequence 2 : Thirteen subject receive oral dose rosuvastatin Day 6 Period 1 Day 14 Period 2 . Oral dos fidaxomicin administer twice daily 10 day Period 1 , accord follow treatment schedule : - Period 1 : Subjects receive fidaxomicin twice daily 5 day ( Days 1 5 ) . On Day 6 , single oral dose rosuvastatin administer simultaneously oral dose fidaxomicin morning . Twice daily treatment fidaxomicin continue end Day 10 . - Period 2 : Subjects receive single oral dose rosuvastatin Day 14 , follow 5-day PK sampling period . Subjects discharge Day 19 assessment perform medical reason prolong stay . In sequence , subject return clinical unit End Study Visit ( ESV ) 7 14 day ( early ) discharge .</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>The subject Body Mass Index ( BMI ) range 18.5 30.0 kg/m2 . The subject weigh least 50 kg Screening . Male subject female spouse/partner childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period 90 day final study drug administration . The subject must donate sperm start Screening throughout study period least 90 day final study drug administration . The subject history current Clostridium difficile infection . The subject history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug . The subject irregular defecation pattern .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Intestinal Absorption</keyword>
	<keyword>Fidaxomicin</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Multiple Doses</keyword>
	<keyword>Single Doses</keyword>
</DOC>